Suryaa Business Desk: Leading consumer healthcare giant 'Haleon' got an unexpected shock in the third quarter. Cough in the international market,... Leading consumer healthcare giant 'Haleon' got an unexpected shock in the third quarter. The company's financial results fell short of expectations due to a significant drop in demand for medicines to treat respiratory diseases like cough, cold and flu in the international market. In this context, Helion's management has released an official statement drastically reducing their full-year revenue growth estimates for the current financial year.
This leading healthcare company, which was earlier split from GSK, is facing severe pressure in the global market with the latest developments. The company's organic revenue growth was limited to just 2.6 percent in the third quarter due to poor performance in goods and over-the-counter (OTC) drug sales. Falling sales of respiratory drugs in key markets such as North America and China, as well as regulatory changes on Centrum Vitamin products in China, had a severe impact on the company's revenue. Due to this, the company revealed that the full-year revenue growth rate, which was previously estimated at 3 to 5 percent, has been reduced to approximately 2.5 percent. As a result, Hellion's shares suffered a huge fall in the stock market.
Despite the slowdown in business growth, the management clarified that the company's cost control measures and productivity improvements have kept operating profit expectations stable. But in the future, the CEO warned employees through an internal memo that tough decisions would have to be taken to survive the market competition and further improve the company's performance. Hellion is making plans to regain investor confidence by accelerating innovation and changing sales strategies in the coming days.